- CEO
- Jie Min Luo
- Full Time Employees
- 1,175
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 39 Dingshan Road Xiamen FU China 361027
- IPO Date
- Aug 2, 2017
- Business
- Amoy Diagnostics Co., Ltd. develops and manufactures precision oncology diagnostic products primarily focused on molecular diagnostics for cancer care. Its main products include gene mutation detection kits, gene amplification detection kits, nucleic acid extraction kits, and comprehensive gene panels such as the AmoyDx homologous recombination deficiency (HRD) focus panel, HRD complete panel, and the CGP master panel that detect genomic signatures including HRD, MSI, TMB, and various gene mutations including EGFR, ALK, ROS1, KRAS, NRAS, BRAF, and more. The product portfolio also features PCR panels tailored for colorectal cancer, thyroid cancer, and other precision molecular tests designed to accelerate biomarker identification and cancer treatment research. Amoy Diagnostics operates a wide-ranging molecular diagnostic product line under its Super-ARMS and AmoyDx brands.
Founded in 2008 and headquartered in Xiamen, China, Amoy Diagnostics has established a robust presence with extensive operations in China and expanding international reach in markets such as Japan, South Korea, and the Asia-Pacific region. The company prioritizes innovation, recently achieving milestone regulatory approvals including China’s first NGS-based companion diagnostic kit approved for both tissue and plasma samples, providing enhanced flexibility for clinical precision testing.
Recent major developments include strategic partnerships and collaborations with leading pharmaceutical firms such as AstraZeneca under a Master Collaboration Agreement to develop companion diagnostic programs in China, the EU, and Japan; a collaborative agreement with Boehringer Ingelheim for companion diagnostic development for lung cancer therapies; and an MoU with Janssen Pharmaceutical Companies for strategic cooperation in biomarker research, patient management, and market access. Amoy Diagnostics also expanded its diagnostic offerings with the launch of advanced PCR panels for cancer mutation detection and has strengthened its global distribution network with over 100 distributors internationally. Its products have secured multiple Innovative Medical Device designations by China’s NMPA, underscoring its commitment to advancing precision oncology globally. The company continues focusing on product innovation, international market expansion, and deeper engagement with global biopharmaceutical partners to accelerate precision oncology solutions beyond China.